Wellbutrin (bupropion) causes seizures because it raises norepinephrine levels in the brain, which overstimulates certain receptors and lowers the threshold at which neurons fire uncontrollably. At standard therapeutic doses, the risk is low, around 0.1% to 0.4% depending on the formulation, but it climbs steeply with higher doses, and certain medical conditions or behaviors can multiply it further. The seizure risk is real enough to carry a prominent place in the drug’s prescribing information, yet the story behind who is actually vulnerable and why is more layered than a simple warning label conveys.
How Bupropion Lowers the Seizure Threshold
Bupropion works by blocking the reuptake of two brain chemicals: norepinephrine and dopamine. That mechanism is what makes it effective for depression and smoking cessation, but it also drives the seizure risk. As norepinephrine accumulates in the spaces between neurons, it stimulates a specific type of receptor (alpha-1 adrenergic receptors) that increases brain arousal and excitability. When that excitation passes a tipping point, normal electrical activity in the brain can cascade into a seizure.1PubMed Central. Analysis of the relationship between antidepressants and seizures based on the food and drug administration’s adverse event reporting system database
This is different from how most other antidepressants interact with seizure risk. SSRIs and SNRIs, for instance, primarily affect serotonin, and at therapeutic doses they appear to have a neutral or even mildly protective effect against seizures. Bupropion’s reliance on norepinephrine and dopamine pathways puts it in a smaller, higher-risk category. A large pharmacovigilance analysis covering reports from 1967 to 2023 found that bupropion had the highest seizure-related reporting ratio among individual antidepressant drugs, with a disproportionality estimate of 8.57, considerably higher than any antidepressant class as a whole.2PubMed. Global burden of antidepressant-associated seizures from 1967 to 2023: A comparative analysis of the international pharmacovigilance database
That number sounds alarming, but context matters. Pharmacovigilance databases capture reports, not controlled measurements of incidence. They are useful for spotting signals and comparing drugs to one another, but they tend to overrepresent well-known side effects because clinicians are primed to report them. The actual seizure rate at recommended doses, as discussed below, is quite small.
How Dose Shapes the Risk
Bupropion’s seizure risk is famously dose-dependent. For the sustained-release formulation (Wellbutrin SR), the seizure incidence is roughly 0.1% at doses up to 300 mg per day. For the older immediate-release formulation, that figure rises to about 0.4% at doses up to 450 mg per day.3Psychopharmacology Institute. Antidepressant Basics Part 1: SSRIs and Bupropion – Section: Adverse Effects Above those ceilings, the risk does not just creep upward; it jumps. Historical data showed seizure rates in the range of 0.5% to nearly 5% at supertherapeutic doses, depending on the population and study design.4Epilepsy & Behavior. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: A review of the evidence – Section: 2 Do antidepressant drugs really have proconvulsant properties?
This steep dose-response curve is why the maximum recommended dose for Wellbutrin SR is 400 mg per day and why single doses are capped (typically no more than 200 mg at once for the SR form). It is also why the extended-release (XL) formulation was developed: by releasing the drug more slowly into the bloodstream, it avoids the sharp peak blood levels that the immediate-release version produces. That peak concentration matters because seizures tend to correlate with how high bupropion levels spike, not just with total daily exposure.
What Happens in an Overdose
The dose-dependency of seizure risk means that overdose is one of the most dangerous scenarios with bupropion. In a study of patients who overdosed on extended-release bupropion, nearly a third experienced seizures, with the first seizure occurring anywhere from 30 minutes to 24 hours after ingestion. Among those who seized, about half went on to have additional seizures.5PubMed. Incidence and onset of delayed seizures after overdoses of extended-release bupropion The delayed onset is a particular concern with extended-release preparations because a patient may appear stable for hours before seizing.6CMAJ. Bupropion abuse and overdose – Section: Seizures are a hallmark of toxicity
Beyond seizures, bupropion overdose can produce tremor, confusion, agitation, hallucinations, a rapid heart rate, and in severe cases, coma.7PubMed Central. Seizures after overdoses of bupropion intake Notably, seizures from overdose can occur in people with no history of epilepsy, reinforcing that bupropion’s pro-convulsant mechanism is pharmacological, not dependent on an underlying seizure disorder. Emergency departments treating suspected bupropion overdoses typically observe patients for an extended window, especially if an extended-release product was ingested.
Eating Disorders and the Bulimia Warning
One of the earliest and most dramatic risk signals for bupropion-related seizures came from a clinical trial in people with bulimia. In a controlled study of 55 patients taking bupropion for bulimia, four experienced grand mal seizures, a rate far higher than anything seen in depression trials at the time. The researchers recommended against prescribing bupropion to bulimic patients until the mechanism could be better understood.8PubMed Central. Treatment of bulimia with bupropion: a multicenter controlled trial
The leading explanation is that the purging and restrictive eating behaviors common in bulimia cause electrolyte imbalances, particularly low sodium, potassium, and magnesium. These electrolyte disturbances independently lower the seizure threshold. When bupropion pushes that threshold further down via its norepinephrine-driven mechanism, the combined effect is enough to trigger seizures at doses that would otherwise be safe. The same logic extends to people with anorexia nervosa or any condition that produces significant metabolic disruption. Bupropion’s prescribing information has carried a contraindication for bulimia and anorexia ever since these findings.
Alcohol Withdrawal
Abrupt withdrawal from heavy alcohol use is itself a well-known trigger for seizures, because the brain adapts to the depressant effects of alcohol and becomes hyperexcitable when alcohol is suddenly removed. Adding bupropion into that picture makes things worse. Animal research has shown that alcohol significantly lowers the seizure threshold when co-administered with bupropion, and clinical observation confirms that the combination is risky in humans.9PubMed Central. Alcohol significantly lowers the seizure threshold in mice when co-administered with bupropion hydrochloride
This applies specifically to people undergoing abrupt cessation of heavy drinking, not to someone who has an occasional glass of wine. If you are being started on bupropion and have a history of heavy alcohol use, your prescriber needs to know, and any reduction in drinking ideally should be gradual rather than sudden. The prescribing information lists abrupt discontinuation of alcohol (and benzodiazepines, for similar reasons) as a contraindication.
Kidney Impairment and Drug Accumulation
Bupropion is metabolized in the liver and its breakdown products are cleared through the kidneys. When kidney function is reduced, bupropion itself accumulates in the bloodstream. A pharmacokinetic study found that patients with significant kidney impairment had bupropion levels roughly double those of healthy controls, with the drug’s half-life increasing by about 140%.10PubMed Central. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites In practical terms, a standard dose in someone with kidney problems can produce the same blood levels as a supertherapeutic dose in someone with normal kidneys. Since seizure risk tracks with blood concentration, this makes kidney impairment a meaningful risk factor even when the prescribed dose is within guidelines.
Clinicians typically reduce bupropion doses or extend the interval between doses for patients with reduced kidney function, but the degree of adjustment is not always standardized. If you have chronic kidney disease and are being prescribed bupropion, it is worth asking whether your dose has been adjusted and whether monitoring would be appropriate.
Genetics and How Your Body Processes Bupropion
The liver enzyme primarily responsible for breaking down bupropion is called CYP2B6. People carry different genetic variants of this enzyme, and those variants affect how quickly or slowly bupropion is metabolized. A meta-analysis of pharmacogenetic studies found that people carrying the CYP2B6*6 variant, one of the more common reduced-function variants, had significantly lower levels of bupropion’s main active metabolite, hydroxybupropion.11PubMed. Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis At first glance, that might sound protective, since a metabolite being lower might seem to reduce toxicity. But the picture is more complicated.
When the enzyme works slowly, bupropion itself sticks around longer and at higher concentrations, even if its metabolites are reduced. A steady-state study in human subjects confirmed that carriers of the CYP2B6*6 allele had roughly a third less hydroxybupropion but showed altered ratios of the parent drug to its metabolites.12PubMed Central. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state More broadly, research in Chinese patients confirmed that CYP2B6 genetic variants meaningfully alter how the drug behaves in the body, enough to warrant personalized dosing.13PubMed Central. Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects
Pharmacogenomic testing for CYP2B6 is available but not routinely ordered before starting bupropion. It is most often done after a patient has an unexpected reaction or in clinical settings where pharmacogenomic panels are standard. This is an area where the science is ahead of common practice. Slow metabolizers are walking around with higher bupropion levels than their prescriber expects, and most of the time it does not cause a problem, but in the occasional unlucky combination of a slow metabolism plus another risk factor, it can be the difference between a seizure and no seizure.
How Bupropion Compares to Other Antidepressants
The seizure association with bupropion sometimes creates the impression that antidepressants in general are dangerous in this regard. The evidence does not support that. A landmark analysis of FDA Phase II and III clinical trial data across several antidepressant classes found that patients randomized to receive an antidepressant actually had a lower overall seizure rate than patients receiving placebo. The seizure incidence in the placebo group was 19 times higher than the general population, suggesting that depression itself raises seizure susceptibility. The two drugs that bucked this trend, showing a higher seizure rate than placebo, were bupropion and clomipramine (a tricyclic antidepressant).4Epilepsy & Behavior. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: A review of the evidence – Section: 2 Do antidepressant drugs really have proconvulsant properties?
In pharmacovigilance data, the broader antidepressant classes most often reported alongside seizures were tricyclic antidepressants as a group, followed by SSRIs and then SNRIs. But when you look at individual drugs rather than classes, bupropion stands out, with a reporting odds ratio of 8.57, ahead of even clomipramine at 4.69.2PubMed. Global burden of antidepressant-associated seizures from 1967 to 2023: A comparative analysis of the international pharmacovigilance database This does not mean bupropion causes seizures eight times more often than average; the ratio reflects how disproportionately seizure reports cluster around bupropion compared to its overall adverse-event profile. But it does confirm that among commonly prescribed antidepressants, bupropion occupies a uniquely elevated tier of seizure risk.
Children, Adolescents, and Accidental Ingestion
Bupropion is prescribed to adolescents for depression and ADHD, and poisoning data show that outcomes differ markedly by age. A study comparing pediatric bupropion ingestions found that adolescents were far more likely to seize than younger children. About 41% of adolescents in the study experienced seizures, compared to just 3% of younger kids. The difference was largely driven by intent: adolescents were more likely to have taken the drug deliberately in overdose, while younger children’s exposures tended to be unintentional and involved smaller amounts.14PubMed Central. Pediatric Bupropion Ingestions in Adolescents vs. Younger Children-a Tale of Two Populations
Still, even small children can have serious reactions at sufficiently high doses. A case report documented multiple seizures, hallucinations, and tachycardia in a young child who ingested roughly 48 mg per kilogram of body weight of extended-release bupropion.15PubMed. Multiple seizures after bupropion overdose in a small child The broader trend is concerning: the number of bupropion poisonings in children and adolescents, along with the resulting harm, has been rising steadily since 2012.16PubMed. Bupropion: Does Its Efficacy Outweigh Potential Morbidity and Lethality? Bupropion should be stored securely, and caregivers should understand that a handful of pills swallowed by a toddler is a genuine emergency, not a “wait and see” situation.
The Salt Formulation Variable
A detail that rarely makes it into patient-facing information is that bupropion comes in two different salt forms: hydrochloride (HCl) and hydrobromide (HBr). The older and more widely prescribed version uses HCl, while a newer branded product (Aplenzin) uses HBr. In animal studies, the difference turned out to be significant. Bupropion HCl induced roughly ten times more cortical seizures in mice than the equivalent dose of bupropion HBr, and in rats, HCl caused seizure activity in all animals tested while HBr caused it in fewer than half.17Neuropsychiatric Disease and Treatment. Electroencephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents
Whether this translates into a clinically meaningful difference in seizure risk for humans remains an open question. Animal models of seizure susceptibility do not always predict human outcomes perfectly, and no head-to-head human trial has compared seizure rates between the two salts. The HBr formulation’s marketing has highlighted these animal findings, but the practical takeaway for most patients is that they are likely taking the HCl version and the risk profile described throughout this article applies to that form. If seizure risk is a particular concern for you, asking your prescriber about the HBr option is reasonable, with the caveat that human evidence is still limited.
Practical Risk Factors at a Glance
Pulling together the evidence, the situations that raise bupropion-related seizure risk fall into a few recognizable categories:
- Dose above guidelines: Taking more than the recommended maximum, whether through prescription error, intentional overdose, or doubling up on a missed dose, is the single biggest driver of seizure risk.
- Eating disorders: Bulimia and anorexia create electrolyte disturbances that compound bupropion’s own threshold-lowering effect. Bupropion is formally contraindicated in these patients.
- Abrupt alcohol or sedative withdrawal: The brain’s rebound excitability during withdrawal stacks with bupropion’s mechanism.
- Kidney impairment: Reduced clearance leads to drug accumulation, effectively turning a standard dose into a higher-than-intended one.
- Genetic variation in CYP2B6: Slow metabolizers clear bupropion more slowly, resulting in higher parent drug levels.
- History of seizures or head trauma: A brain that has seized before, or that has structural damage, generally has a lower seizure threshold to begin with.
- Concurrent medications: Other drugs that lower the seizure threshold or that inhibit CYP2B6 can increase bupropion exposure. Common examples include certain antipsychotics and tramadol.
Most people taking bupropion at prescribed doses and without the risk factors above will never experience a seizure. The drug has been on the market since the late 1980s, is prescribed to millions of people annually, and has a well-understood safety profile. The point is not to avoid bupropion but to ensure that prescribers and patients are aware of the specific situations where the risk escalates meaningfully beyond its baseline.
Why the Immediate-Release Formulation Mostly Disappeared
The original Wellbutrin was an immediate-release tablet dosed three times a day. It had the highest seizure rate of any formulation, about 0.4% at doses up to 450 mg per day, because each dose produced a rapid spike in blood levels.3Psychopharmacology Institute. Antidepressant Basics Part 1: SSRIs and Bupropion – Section: Adverse Effects The sustained-release (SR) and especially the extended-release (XL) reformulations were designed specifically to flatten that peak. The SR version, dosed twice daily, brought the seizure rate down to about 0.1% at recommended doses. The XL version, dosed once daily, maintains a smoother blood-level profile still.
The immediate-release form has not been withdrawn from the market, but prescribers overwhelmingly choose SR or XL for new patients. Generic versions of both are widely available. If you are taking bupropion and are unsure which formulation you are on, your pharmacy label will specify IR, SR, or XL. Switching between formulations without guidance is risky, because the same total daily milligrams can produce very different peak concentrations depending on how the tablet releases the drug.